Atara Biotherapeutics (ATRA) ATA188 Likely To Progress to Ph2 - William Blair

William Blair analyst Matt Phipps reiterated an Outperform rating on Atara Biotherapeutics (NASDAQ: ATRA) after the company reported Phase I results with ATA188 in progressive multiple sclerosis (MS) patients at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The therapy appears very tolerable, with no dose limiting toxicities or laboratory abnormalities reported but efficacy data difficult to interpret due to the small patient numbers, lack of a control arm, and minimal details provided on the specific changes in endpoints from baseline.

The analyst stated " Although it is difficult to make meaningful conclusions from the efficacy data to date, we believe it is supportive of advancement into the Phase Ib trial given the trends observed in cohort 2".

For an analyst ratings summary and ratings history on Atara Biotherapeutics click here. For more ratings news on Atara Biotherapeutics click here.

Shares of Atara Biotherapeutics closed at $14.95 yesterday.

You May Also Be Interested In

• ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 10c
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• UBS Reiterates Buy Rating on HF Sinclair (DINO)